{"id":"gsp-301-ns","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303572","moleculeType":"Small molecule","molecularWeight":"427.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSP 301 NS represents a nasal spray delivery system developed by Glenmark Specialty. The specific molecular mechanism and target are not publicly disclosed in readily available sources. The 'NS' designation typically indicates a nasal spray formulation, which allows for non-invasive administration and potentially improved bioavailability or patient compliance compared to oral or injectable routes.","oneSentence":"GSP 301 NS is a nasal spray formulation designed to deliver its active pharmaceutical ingredient through the nasal mucosa for systemic or local therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:40.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02318303","phase":"PHASE2","title":"To Study GSP 301 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-12","conditions":"Seasonal Allergic Rhinitis","enrollment":1111},{"nctId":"NCT02709538","phase":"PHASE3","title":"Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-04","conditions":"Perennial Allergic Rhinitis","enrollment":601},{"nctId":"NCT03463031","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2018-03-16","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":446},{"nctId":"NCT02631551","phase":"PHASE3","title":"Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-03","conditions":"Seasonal Allergic Rhinitis","enrollment":1180},{"nctId":"NCT03444506","phase":"PHASE2","title":"Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-01-27","conditions":"Seasonal Allergic Rhinitis","enrollment":180},{"nctId":"NCT02870205","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-08","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":1176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSP 301 NS","genericName":"GSP 301 NS","companyName":"Glenmark Specialty S.A.","companyId":"glenmark-specialty-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}